Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial - The Lancet Oncology
Adherence of early postmenopausal breast cancer patients to exemestane... | Download Table
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane - ScienceDirect
Differences between the non-steroidal aromatase inhibitors anastrozole and letrozole – of clinical importance? | British Journal of Cancer
Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin | SpringerLink
The Third-Generation Aromatase Inhibitors
Aromatase inhibition in the treatment of advanced breast cancer: is there a relationship between potency and clinical efficacy? | British Journal of Cancer
Molecules | Free Full-Text | Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target
Role of aromatase inhibitors in breast cancer | British Journal of Cancer
Acquired resistance to aromatase inhibitors: where we stand! in: Endocrine-Related Cancer Volume 25 Issue 5 (2018)
Steroidal and non-steroidal third-generation aromatase inhibitors induce pain-like symptoms via TRPA1 | Nature Communications
![PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0c397df0e388d36e159595eed864e369e42b123f/3-Figure1-1.png "PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar")
PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar
Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials - The Lancet Oncology
JCM | Free Full-Text | Aromatase Inhibitors and Risk of Metabolic and Cardiovascular Adverse Effects in Breast Cancer Patients—A Systematic Review and Meta-Analysis
Non steroidal aromatase inhibitors - Wikipedia
Frontiers | Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management
Femara, Arimidex and Aromasin: The Aromatase Inhibitors
Letrozole: Advancing Hormone Therapy in Breast Cancer - Rebecca J Lee, Anne C Armstrong, Andrew M Wardley, 2012
Sequencing of aromatase inhibitors | British Journal of Cancer
Aromatase Inhibitors
Foods To Eat & Avoid During Aromatase Inhibitor Treatment | Food for Breast Cancer
Intra-individual change in plasma estrogen concentrations during... | Download Scientific Diagram
Aromatase Inhibitors and Joint Pain: Causes and Ways of Managing - OWise UK
![PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/0c397df0e388d36e159595eed864e369e42b123f/5-Table1-1.png "PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar")
PDF] Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. | Semantic Scholar
Changes in serum estrogenic activity during neoadjuvant therapy with letrozole and exemestane - ScienceDirect
PDF) Switching to letrozole or exemestane improves hot flushes, mood and quality of life in tamoxifen intolerant women
